Nantahala Capital Management
Overview
Nantahala Capital Management is a hedge fund manager that utilizes a long-term fundamental value investing methodology with a primary focus on small to mid-sized U.S. companies, investing in equity, fixed-income, and equity-derivative securities.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Obsidian Therapeutics | Apr 2026 | Private Equity | Co-investor |
| Senti Biosciences | Dec 2024 | PIPE | Co-investor |
| Kiora Pharmaceuticals | Feb 2024 | Private Placement | Co-investor |
| Femasys Inc. | Aug 2026 | Private Placement | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Nantahala Capital Management based?
Nantahala Capital Management is headquartered in New Canaan, Connecticut, United States.
When was Nantahala Capital Management founded?
Nantahala Capital Management was founded in 2004.
How many portfolio companies does Nantahala Capital Management have?
Nantahala Capital Management has 5 portfolio companies in Caplight's dataset.
What are some companies in Nantahala Capital Management's portfolio?
Portfolio companies visible on Caplight include Obsidian Therapeutics, Senti Biosciences, Kiora Pharmaceuticals, Femasys Inc..
What was Nantahala Capital Management's most recent investment shown here?
Nantahala Capital Management's most recent investment in this portfolio sample was in Femasys Inc. in 2026.
What sectors does Nantahala Capital Management focus on?
Nantahala Capital Management focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Nantahala Capital Management focus on?
Stage focus information for Nantahala Capital Management is not publicly available.
What is Nantahala Capital Management's AUM?
Nantahala Capital Management's assets under management are estimated between $2.3B and $2.6B.